Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study

Table 2

Baseline characteristics of subjects treated with azelnidipine and temocapril.

	Azelnidipine	Temocapril	𝑃 value
𝑛	23	21
Male/Female (𝑛), (%)	18/5 (78/22)	15/6 (71/29)	.60
Age (years)	60.8±7.9	61.0±8.5	.96
BMI (Kg/m^2)	25.6±4.3	25.8±3.3	.85
Period of HT (yr)	5.3±5.7	9.0±12.8	.21
Systolic BP (mmHg)	155.1±11.1	157.2±10.2	.52
Diastolic BP (mmHg)	97.8±5.7	95.2±5.4	.14
Fasting BG (mg/dL)	147.4±27.5	132.3±19.4	.04
TG (mg/dL)	127.3±54.7	129.1±61.3	.92
LDL-cholesterol (mg/dL)	136.1±39.5	137.0±39.0	.94
Serum Cr (mg/dL)	0.75±0.12	0.77±0.15	.58

HT: hypertension, BP: blood pressure, BG: blood glucose, TG: triglyceride, LDL: low density lipoprotein, and Cr: creatinine (mean±SD).